Pembrolizumab (KEYTRUDA®) and PDS0101
PDS0101-HNC-201
Phase 2 other completed
Quick answer
Pembrolizumab (KEYTRUDA®) and PDS0101 for Metastatic Head and Neck Cancer is a Phase 2 program (other) at PDS Biotechnology Corp with 1 ClinicalTrials.gov record(s).
Program details
- Company
- PDS Biotechnology Corp
- Indication
- Metastatic Head and Neck Cancer
- Phase
- Phase 2
- Modality
- other
- Status
- completed